Retatrutide in Dallas · Reta at GoodmorrowMore life
ahead.
The long walks. The family trips. Feeling more like you. Meet Reta, a new possibility in weight care, and be ready for what comes next.
25%average body weight lost12 mg · 80 weeks · TRIUMPH-1
Retatrutide is still in clinical trials and is not FDA-approved. Join for updates about future availability.
Goodmorrow campaign imagery. Not patients.Picture the possibility
See the change.
Imagine the possibilities.
At 180 lb, a 25% change is 45 lb. Slide to see the study results in numbers you can picture.
Slide to explore, or type a number above.
Defaults to today + 80 weeks, the trial duration. Retatrutide is investigational, in phase 3 development, and not commercially available today.
Change the illustration date
Defaults to today in Dallas. This is a calendar illustration, not a treatment start or availability date.
Your study illustration
at the 80-week checkpoint
45 lb less than 180 lb, using the 25% study average. An illustration, not a prediction.
An illustration using group averages, not a personal prediction or target weight. These two analyses are not a range of expected individual outcomes. A clinician determines whether treatment and weight loss are appropriate for you.
Be ready for what’s nextBased on TRIUMPH-1’s 12 mg group at 80 weeks in adults with obesity or overweight and a weight-related condition, without diabetes. Numbers rounded to the nearest pound. Individual results and timing vary. Read this analysis ↗
Your entries stay in this browser session and are not included in the signup form.
The possibilities behind the percentages
What would you
say yes to?
Weight, movement, sleep. Explore the research through the moments that matter to you.
A quarter of starting body weight
The outfit.
The trip.
The confidence.
Picture what feeling lighter could open up. In the weight-loss trial, the average change was a quarter of starting body weight.
Put that in pounds25.0%average body weight lost
At 80 weeks with 12 mg in TRIUMPH-1, versus 3.9% with placebo. This analysis accounts for treatment discontinuation.
Read the findings ↗A promising finding for knee pain
The long walk.
The dance floor.
The grandkids.
Those are the moments that make easier movement matter. Researchers saw substantial reductions in knee pain scores in participants with obesity and knee osteoarthritis.
Follow the next chapterup to73.1%reduction in knee pain scores
Up to 73.1% from baseline in the TRIUMPH-1 knee osteoarthritis group at 80 weeks. Lilly’s analysis assumes continued treatment; this does not establish joint repair.
Read the findings ↗A promising finding for sleep apnea
Better nights.
More possibility
in every day.
Rest is part of the bigger picture. In one sleep-apnea trial, about half reached remission or mild sleep apnea without daytime sleepiness.
Explore the sleep resultsup to51.6%reached remission or mild sleep apnea
Up to 51.6% reached remission OR mild OSA without daytime sleepiness, versus 12.5% with placebo. Adults with obesity and OSA without type 2 diabetes, at 80 weeks.
Read the findings ↗These are different study outcomes, not a combined prediction for one person. Individual results vary. Digestive side effects were common, and benefits and risks are still being studied.
The full picture: side effects and study context
Digestive side effects were common. In TRIUMPH-1, 42.4% of participants in the 12 mg group reported nausea, versus 14.8% with placebo; 11.3% stopped because of adverse events, versus 4.9%. Research is ongoing, and individual outcomes vary. Trial safety results ↗
The science, simply
Meet the three
behind the possibility.
Retatrutide activates three hormone receptors: GLP-1, GIP and glucagon. These pathways help regulate appetite, blood sugar and energy use. Researchers are testing what this combination can achieve in a once-weekly injection.
How Reta compares with tirzepatideIn participants’ own words
Real words.
New possibilities.
Published interviews offer a glimpse of what some people experienced in a phase 2 retatrutide trial.
I can actually move. I can actually do stuff.
I didn’t crave the sweets like I usually did before the trial
Short excerpts from a Lilly-funded qualitative study of 40 volunteers, including 36 who received retatrutide. Participants were paid for the interviews. These are individual research experiences, not Goodmorrow patient testimonials or typical-results claims. Some participants also reported side effects or disappointing results. Read the published interviews
Goodmorrow · Dallas, Texas
Dallas, let’s
look ahead.
Our goal is to bring retatrutide care to North Texas as soon as FDA approval, lawful supply and our clinical readiness allow.
Join now for the milestones that matter, from approval news to availability at Goodmorrow.
Keep me in the loopWhere things stand · October 29, 2026
- 01
Promising phase 3 results
Research is advancing across obesity and related conditions.
- 02
FDA submission ahead
Lilly has stated a planned U.S. submission in Q1 2027. No approval or launch date has been announced.
- 03
Future care at Goodmorrow
After approval and lawful supply, our clinical team would assess individual eligibility. We do not offer Reta today.
The Goodmorrow Reta list
Your next chapter.
Stay close to it.
Be among the first to hear when retatrutide is legally available through Goodmorrow.
Free to join. No payment or health history needed. Joining does not reserve medication, guarantee a prescription or set a treatment date.
Get on the list.
Reta research, approval news and Dallas availability updates, in your inbox.
A little more clarity.
What is Reta?
Reta is a common nickname for retatrutide, Eli Lilly’s investigational medicine that activates GLP-1, GIP and glucagon receptors. It is being studied for weight management and related conditions.
Can I get retatrutide in Dallas now?
Retatrutide is not FDA-approved and Goodmorrow does not currently offer it. FDA says retatrutide cannot be used in compounding under federal law. The interest list is for updates about future lawful availability.
When will retatrutide be FDA-approved?
There is no announced FDA approval date. Lilly has stated that it plans to submit retatrutide in the U.S. in the first quarter of 2027. Filing, approval and pharmacy availability are separate steps. Information checked October 29, 2026.
Why do some headlines say 28% weight loss?
TRIUMPH-1 reported two analyses. At 12 mg and 80 weeks, the estimate accounting for treatment discontinuation was 25.0% average weight loss. The estimate assuming participants continued treatment was 28.3%. Both are group averages, not a promise of personal results.
Did retatrutide eliminate sleep apnea?
Trials found meaningful improvements in obstructive sleep apnea. The frequently cited ‘about half’ figure combines remission with mild sleep apnea without daytime sleepiness in one study population. It does not mean half of all patients were cured. Continue prescribed sleep-apnea treatment unless your clinician changes it.
Is the interest list free?
Yes. Join for retatrutide research, approval and Goodmorrow availability updates by email. No payment or health history is needed. Joining does not reserve supply or guarantee treatment. Medication pricing and eligibility will depend on any eventual approval, supply and clinical assessment.
Research checked October 29, 2026. Educational information, not individual medical advice. Goodmorrow is not affiliated with Eli Lilly. This page does not offer investigational treatment.
Explore the research and sources
Sources
- Research publicationRetatrutide for obesity: TRIUMPH-1 phase 3 results New England Journal of Medicine, 2026
- Secondary sourceLilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Eli Lilly via PR Newswire, May 21, 2026
- Manufacturer informationTRIUMPH-1 results for weight, knee osteoarthritis and sleep apnea Eli Lilly (trial sponsor), June 6, 2026
- Secondary sourceRetatrutide in obstructive sleep apnea: late-breaking clinical abstract Journal of Sleep Research, October 19, 2026
- Research publicationPerceived benefits of treatment for obesity with retatrutide: a qualitative study of patients in a phase 2 clinical trial Goetz and colleagues; Lilly-funded research, 2025
- Manufacturer informationRetatrutide phase 3 results and planned U.S. submission in Q1 2027 Eli Lilly, July 23, 2026
- FDA documentFDA’s concerns with unapproved GLP-1 drugs used for weight loss U.S. Food and Drug Administration, Checked October 29, 2026